Disruption of vascular homeostasis in patients with Kawasaki disease: Involvement of vascular endothelial growth factor and angiopoietins

Arthritis and Rheumatism

Volumn 64, Issue 1, 2012, Pages 306-315

  Breunis, Willemijn B ^a   Davila, Sonia ^b   Shimizu, Chisato ^c   Oharaseki, Toshiaki ^d   Takahashi, Kei ^d   Van Houdt, Michel ^a   Khor, Chiea Chuen ^b   Wright, Victoria J ^e   Levin, Michael ^e   Burns, Jane C ^c   Burgner, David ^f,g   Hibberd, Martin L ^b   Kuijpers, Taco W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; TRANSCRIPTION FACTOR; VASCULOTROPIN A; VASCULOTROPIN B;

3' UNTRANSLATED REGION; ARTICLE; AUTOPSY; BINDING SITE; CONVALESCENCE; CORONARY ARTERY; DOWN REGULATION; GENE FREQUENCY; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULARIZATION; VASCULITIS;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; CHILD, PRESCHOOL; CONVALESCENCE; CORONARY VESSELS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, TIE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855266759     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33316     Document Type: Article

References (45)

1. Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H,. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006. J Epidemiol 2008; 18: 167-72.
2. Uehara R, Yashiro M, Nakamura Y, Yanagawa H,. Kawasaki disease in parents and children. Acta Paediatr 2003; 92: 694-7. (Pubitemid 37088678)
3. Burns JC, Glode MP,. Kawasaki syndrome. Lancet 2004; 364: 533-44. (Pubitemid 39070416)
4. Freeman AF, Crawford SE, Cornwall ML, Garcia FL, Shulman ST, Rowley AH,. Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium. Pediatr Cardiol 2005; 26: 578-84. (Pubitemid 43015790)
5. Takeshita S, Kawamura Y, Takabayashi H, Yoshida N, Nonoyama S,. Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. Clin Exp Immunol 2005; 139: 575-9. (Pubitemid 40333270)
6. Augustin HG, Koh GY, Thurston G, Alitalo K,. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-77.
7. Ferrara N,. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611. (Pubitemid 39099316)
8. Hamamichi Y, Ichida F, Yu X, Hirono KI, Uese KI, Hashimoto I, et al. Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions. Pediatr Res 2001; 49: 74-80. (Pubitemid 32015003)
9. Kariyazono H, Ohno T, Khajoee V, Ihara K, Kusuhara K, Kinukawa N, et al. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 2004; 56: 953-9. (Pubitemid 39552779)
10. Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, et al. Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 1998; 44: 596-9. (Pubitemid 28447349)
11. Ohno T, Igarashi H, Inoue K, Akazawa K, Joho K, Hara T,. Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 2000; 159: 424-9. (Pubitemid 30329107)
12. Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y,. Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999; 83: 337-9. (Pubitemid 29066489)
13. Breunis WB, Biezeveld MH, Geissler J, Ottenkamp J, Kuipers IM, Lam J, et al. Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum 2006; 54: 1588-94.
14. Hirose S, Hamashima Y,. Morphological observations on the vasculitis in the mucocutaneous lymph node syndrome: a skin biopsy study of 27 patients. Eur J Pediatr 1978; 129: 17-27. (Pubitemid 8376681)
15. Suzuki A, Miyagawa-Tomita S, Nakazawa M, Yutani C,. Remodeling of coronary artery lesions due to Kawasaki disease: comparison of arteriographic and immunohistochemical findings. Jpn Heart J 2000; 41: 245-56. (Pubitemid 30636369)
16. Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, et al. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 2002; 105: 766-9. (Pubitemid 34157383)
17. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, et al, the International Kawasaki Disease Genetics Consortium. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet 2009; 5: e1000319.
18. Hanahan D,. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50. (Pubitemid 27450640)
19. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-71. (Pubitemid 39453026)
20. Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Ministry of Health and Welfare, 1984.
21. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV,. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60: 1245-9. (Pubitemid 30017507)
22. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW,. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63: 812-6. (Pubitemid 36231981)
23. Mahony S, Benos PV,. STAMP: a web tool for exploring DNA-binding motif similarities. Nucleic Acids Res 2007; 35: W253-8.
24. Ward EG, Grosios K, Markham AF, Jones PF,. Genomic structures of the human angiopoietins show polymorphism in angiopoietin-2. Cytogenet Cell Genet 2001; 94: 147-54. (Pubitemid 34203295)
25. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C,. Protective role of angiopoietin-1 in endotoxic shock. Circulation 2005; 111: 97-105. (Pubitemid 40070850)
26. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-3. (Pubitemid 30208166)
27. Lee KW, Lip GY, Blann AD,. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor Tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110: 2355-60. (Pubitemid 39407339)
28. Lovegrove FE, Tangpukdee N, Opoka RO, Lafferty EI, Rajwans N, Hawkes M, et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One 2009; 4: e4912.
29. Mitsuma W, Kodama M, Hirono S, Ito M, Ramadan MM, Tanaka K, et al. Angiopoietin-1, angiopoietin-2 and Tie-2 in the coronary circulation of patients with and without coronary collateral vessels. Circ J 2007; 71: 343-7. (Pubitemid 46409536)
30. Kumpers P, Lukasz A, David S, Horn R, Hafer C, Faulhaber-Walter R, et al. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care 2008; 12: R147.
31. Fiedler U, Augustin HG,. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552-8. (Pubitemid 44780853)
32. Lobov IB, Brooks PC, Lang RA,. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002; 99: 11205-10. (Pubitemid 34920903)
33. Huang YQ, Li JJ, Karpatkin S,. Identification of a family of alternatively spliced mRNA species of angiopoietin-1. Blood 2000; 95: 1993-9. (Pubitemid 30151637)
34. Li JJ, Huang YQ, Basch R, Karpatkin S,. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 2001; 85: 204-6. (Pubitemid 32140561)
35. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90. (Pubitemid 28133134)
36. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235-9. (Pubitemid 43214752)
37. Fujiwara H, Hamashima Y,. Pathology of the heart in Kawasaki disease. Pediatrics 1978; 61: 100-7. (Pubitemid 8268802)
38. Amano S, Hazama F, Hamashima Y,. Pathology of Kawasaki disease. I. Pathology and morphogenesis of the vascular changes. Jpn Circ J 1979; 43: 633-43. (Pubitemid 10173088)
39. Naoe S, Takahashi K, Masuda H, Tanaka N,. Kawasaki disease: with particular emphasis on arterial lesions. Acta Pathol Jpn 1991; 41: 785-97.
40. Miura M, Garcia FL, Crawford SE, Rowley AH,. Cell adhesion molecule expression in coronary artery aneurysms in acute Kawasaki disease. Pediatr Infect Dis J 2004; 23: 931-6. (Pubitemid 40812780)
41. Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH,. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003; 23: 576-81. (Pubitemid 36438068)
42. Barakat MR, Kaiser PK,. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009; 18: 637-46.
43. Grothey A, Galanis E,. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6: 507-18.
44. Thurston G, Rudge JS, Ioffe E, Papadopoulos N, Daly C, Vuthoori S, et al. The anti-inflammatory actions of angiopoietin-1. EXS 2005: (94); 233-45.
45. Van Meurs M, Kumpers P, Ligtenberg JJ, Meertens JH, Molema G, Zijlstra JG,. Bench-to-bedside review: angiopoietin signalling in critical illness-a future target? Crit Care 2009; 13: 207.